CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...

Investigators aim to establish an optimal dose and explore CER-1236's safety and preliminary anti-tumor activity.

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) has achieved a major milestone in the fight against acute myeloid leukemia ...

Medically reviewed by Archana Sharma, DO Acute myelogenous leukemia (AML), also known as acute myeloid leukemia, is a type of ...

ABOUT CARVYKTI® (CILTACABTAGENE AUTOLEUCEL; CILTA-CEL) ...

An international study led by the University of Colorado Cancer Center has uncovered why a widely used treatment for acute ...

An international study led by the University of Colorado Cancer Center has uncovered why a widely used treatment for acute myeloid leukemia (AML) doesn’t work for everyone. The findings could help ...

Researchers analyzed data from 678 AML patients, the largest group studied to date for this treatment and found that both gene mutations and the maturity of leukemia cells affect how patients ...

AML is a clonal stem cell cancer characterized by the proliferation and maturation arrest of immature myeloid precursor cells, leading to bone marrow failure (Venugopal and Sekeres, 2024). The ...